X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
0
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
Basilea has acquired the rights to PF-07842805 (fosmanogepix), a potential first-in-class, clinical-stage broad-spectrum antifungal treatment candidate for the treatment of Candidemia, including Candida auris, and invasive mold infections.
Lead Product(s): Fosmanogepix
Therapeutic Area: Infections and Infectious Diseases Product Name: PF-07842805
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Basilea Pharmaceutica
Deal Size: $147.0 million Upfront Cash: $37.0 million
Deal Type: Acquisition November 13, 2023
Details:
With this acquisition Pfizer adds Amplyx’s lead compound, Fosmanogepix (APX001) to its pipeline and in addition to this Pfizer has secured ownership of Amplyx's early-stage pipeline that includes potential antiviral (MAU868) and antifungal (APX2039) therapies.
Lead Product(s): Fosmanogepix
Therapeutic Area: Infections and Infectious Diseases Product Name: APX001
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Pfizer Inc
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition April 28, 2021
Details:
At IDWeek 2020, positive data from the Phase 2 clinical trial evaluating fosmanogepix, a novel IV and oral Gwt1 inhibitor, in patients with candidemia will be presented during an oral session at the American Society of Nephrology (ASN) Kidney Week 2020.
Lead Product(s): Fosmanogepix
Therapeutic Area: Infections and Infectious Diseases Product Name: APX001
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 16, 2020
Details:
Topline data from the study indicated fosmanogepix's success rate of 80 percent, meeting the primary endpoint and paving the way to a pivotal trial ahead.
Lead Product(s): Fosmanogepix
Therapeutic Area: Infections and Infectious Diseases Product Name: APX001
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 20, 2020
Details:
Amplyx plans to use this Series C funds to advance the clinical development of the company’s two product candidates, fosmanogepix (APX001) and MAU868 for the treatment of life-threatening fungal infections and BK Virus.
Lead Product(s): Fosmanogepix
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Pfizer Inc
Deal Size: $53.0 million Upfront Cash: Undisclosed
Deal Type: Series C Financing May 19, 2020
Details:
Amplyx has advanced development of its lead program, fosmanogepix (APX001). Enrollment has been completed in a Phase 2 trial evaluating the safety and efficacy of fosmanogepix for the treatment of infections caused by Candida.
Lead Product(s): Fosmanogepix
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 19, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
